Guinea

eLife 2015;10.7554/eLife.09186 - December 8, 2015
DOI: http://dx.doi.org/10.7554/eLife.09186

Abstract

As of November 2015, the Ebola virus disease (EVD) epidemic that began in West Africa in late 2013 is waning. The human toll includes more than 28,000 Ebola virus disease (EVD) cases and 11,000 deaths in Guinea, Liberia, and Sierra Leone, the most heavily-affected countries. We reviewed 66 mathematical modeling studies of the EVD epidemic published in the peer-reviewed literature to assess the key uncertainties models addressed, data used for modeling, public sharing of data and results, and model performance. Based on the review, we suggest steps to improve the use of modeling in future public health emergencies.

Ebola survivor Dr. Richard Sacra experienced eye problems, including vision loss, pain and redness, shortly after he recovered from the disease.

Credit: Chancellor JR, Padmanabhan SP, Greenough TC, Sacra R, Ellison RT III, Madoff LC, et al. Uveitis and systemic inflammatory markers in convalescent phase of Ebola virusdisease. Emerg Infect Dis. 2016 Feb

CLICK HERE - STUDY - CDC - Uveitis and Systemic Inflammatory Markers in Convalescent Phase of Ebola Virus Disease

livescience.com - by Rachael Rettner - November 25, 2015

Ebola survivor Dr. Ian Crozier wasn't the only American to experience eye problems following the disease — a new report describes eye problems in another American doctor who lived through the disease.

Dr. Richard Sacra, who works for the Christian mission organization SIM USA, contracted Ebola last year while caring for pregnant women in Liberia during the rise of the Ebola outbreak there. He was evacuated to the United States for treatment in early September 2014, and was declared Ebola-free after spending about a month in the hospital.

submitted by George Hurlburt

CLICK HERE - STUDY - Interferon-γ Inhibits Ebola Virus Infection

scicasts.com - November 19, 2015

The recent Ebola outbreak in West Africa has claimed more than 11,300 lives and starkly revealed the lack of effective options for treating or preventing the disease. Progress has been made on developing vaccines, but there is still a need for antiviral therapies to protect health care workers and local populations in the event of future outbreaks.

A new study led by University of Iowa virologist Dr. Wendy Maury, suggests that gamma interferon, which is an FDA-approved drug, may have potential as an antiviral therapy to prevent Ebola infection when given either before or after exposure to the virus.

The study, published in the journal PLOS Pathogens, found that gamma interferon, given up to 24 hours after exposure, can inhibit Ebola infection in mice and completely protect the animals from death.

PLOS PATHOGENS  by Marc-Antoine de La Vega,  Derek Stein, and GaryKopinger, University of Manitoba, Canada , Nov. 12, 2015    

Winnipeg, Manitoba, Canada The past year has marked the most devastating Ebola outbreak the world has ever witnessed, with over 28,000 cases and over 11,000 deaths. Ebola virus (EBOV) has now been around for almost 50 years. In this review, we discuss past and present outbreaks of EBOV and how those variants evolved over time. We explore and discuss selective pressures that drive the evolution of different Ebola variants, and how they may modify the efficacy of therapeutic treatments and vaccines currently being developed. Finally, given the unprecedented size and spread of the outbreak, as well as the extended period of replication in human hosts, specific attention is given to the 2014–2015 West African outbreak variant (Makona).

Read complete article.

http://journals.plos.org/plospathogens/article?id=10.1371/journal.ppat.1005221